The Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2023, provides comprehensive information on the irritable bowel syndrome (ibs) treatment market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Irritable Bowel Syndrome (IBS) Treatment Market’s Growth:
The global irritable bowel syndrome (IBS) market size is expected to grow from $2.25 billion in 2022 to $2.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of irritable bowel syndrome (IBS) market is expected to reach $3.82 billion in 2027 at a CAGR of 11.2%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=11978&type=smp
Product innovations have emerged as a key trend gaining popularity in the irritable bowel syndrome (IBS) market. Major irritable bowel syndrome (IBS) market players are concentrating their efforts on creating new and innovative, advanced products to strengthen their position in the market. For instance, in April 2022, Ardelyx, a US-based biotechnology company, launched IBSRELA, a first-in-class treatment for IBS-C in adults. It is the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C). IBSRELA, the first Ardelyx medicine to receive FDA approval, is the first novel mechanism therapy for IBS-C (irritable bowel syndrome-constipation) to be developed in almost ten years, and it provides a significant new treatment option for constipation, bloating, and stomach pain that are symptoms of this crippling disorder.
The irritable bowel syndrome (ibs) treatment market is segmented:
1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
North America was the largest region in the irritable bowel syndrome (ibs) treatment market in 2022.
The table of contents in TBRC’s irritable bowel syndrome (ibs) treatment market report includes:
- Executive Summary
- Irritable Bowel Syndrome (IBS) Treatment Market Characteristics
- Irritable Bowel Syndrome (IBS) Treatment Market Trends And Strategies
- Irritable Bowel Syndrome (IBS) Treatment Market – Macro Economic Scenario
- Irritable Bowel Syndrome (IBS) Treatment Market Segmentation
.
.
.
- Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Benchmarking
- Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Dashboard
- Key Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market
- Irritable Bowel Syndrome (IBS) Treatment Market Future Outlook and Potential Analysis
- Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
